These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Milky appearance of peritoneal fluid in a neonate on peritoneal dialysis due to end-stage renal disease: Answers. Wu X; Vega M; Swartz SJ; Michael M Pediatr Nephrol; 2018 Jan; 33(1):73-76. PubMed ID: 28283762 [No Abstract] [Full Text] [Related]
5. Calcium Channel Blocker-Associated Chyloperitoneum in Patients Receiving Peritoneal Dialysis: A Systematic Review. Kim S; Yu YM; Kwon J; Yoo H; Jung SH; Lee E Int J Environ Res Public Health; 2019 Apr; 16(8):. PubMed ID: 31013922 [TBL] [Abstract][Full Text] [Related]
6. Incidence of angio-oedema associated with ARBs, ACE inhibitors, and aliskiren. BMJ; 2012 Oct; 345():e6941. PubMed ID: 23077371 [No Abstract] [Full Text] [Related]
7. Aliskiren combined with losartan in type 2 diabetes and nephropathy. Parving HH; Persson F; Lewis JB; Lewis EJ; Hollenberg NK; N Engl J Med; 2008 Jun; 358(23):2433-46. PubMed ID: 18525041 [TBL] [Abstract][Full Text] [Related]
8. Chyloperitoneum in a peritoneal dialysis patient. Levy RI; Wenk RE Am J Kidney Dis; 2001 Sep; 38(3):E12. PubMed ID: 11532714 [TBL] [Abstract][Full Text] [Related]
9. A comparison of the antihypertensive and anti-inflammatory effects of aliskiren and ramipril add-on therapy in peritoneal dialysis patients--a pilot open label study. Makówka A; Olejniczak-Fortak M; Nowicki M Kidney Blood Press Res; 2012; 36(1):18-25. PubMed ID: 22777192 [TBL] [Abstract][Full Text] [Related]
10. [Aliskiren (Rasilez), direct renin inhibitor]. Scheen AJ; Piérard L; Krzesinski JM Rev Med Liege; 2008 Sep; 63(9):564-9. PubMed ID: 19051513 [TBL] [Abstract][Full Text] [Related]
11. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity. Dalla Vestra M; Simioni N; Masiero A Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162 [TBL] [Abstract][Full Text] [Related]
13. [Possible role of Lercanidipine in Chiloperitoneum occurrence in CAPD: a case-report]. Nicotera R; Chiarella S; Placida G; De Paola L; D'Onofrio G; Panzino MT; Panzino A; Mileti S; Pinciaroli AR; Coppolino G G Ital Nefrol; 2018 Jul; 35(4):. PubMed ID: 30035445 [TBL] [Abstract][Full Text] [Related]
14. Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease. Abe M; Suzuki H; Okada K; Maruyama N; Inoshita A; Baba S; Takashima H; Soma M Heart Vessels; 2013 Jul; 28(4):442-52. PubMed ID: 22618635 [TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy, safety and tolerability of Aliskiren Monotherapy (AM): an umbrella review of systematic reviews. Zhao Q; Shen J; Lu J; Jiang Q; Wang Y BMC Cardiovasc Disord; 2020 Apr; 20(1):179. PubMed ID: 32303191 [TBL] [Abstract][Full Text] [Related]
16. Aliskiren (Tekturna) a new weapon to battle the silent killer. Laustsen G Nurse Pract; 2007 Jul; 32(7):6-7. PubMed ID: 17595578 [No Abstract] [Full Text] [Related]
17. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Persson F; Desai AS; Nicolaides M; Richard A; Xiang Z; Brunel P; Pfeffer MA; N Engl J Med; 2012 Dec; 367(23):2204-13. PubMed ID: 23121378 [TBL] [Abstract][Full Text] [Related]
18. Not ready for prime time: aliskiren for treatment of hypertension or proteinuria in children. Flynn JT Pediatr Nephrol; 2011 Mar; 26(3):491-2. PubMed ID: 21161281 [No Abstract] [Full Text] [Related]